Seres Therapeutics and Nestlé Health Science sign a non-binding MoU for Seres to sell bacterial infection drug Vowst.

Seres Therapeutics and Nestlé Health Science have signed a non-binding MoU for Seres to sell its bacterial infection drug, Vowst, and related intellectual property rights. The deal, subject to final approval, is expected to be completed within 90 days, with Seres receiving capital infusions, including an undisclosed upfront payment. Proceeds will be used to repay Seres' debt and fund advancement of microbiome product candidates SER-155 and others.

June 06, 2024
7 Articles

Further Reading